Manuel Cobo

28.0k total citations · 4 hit papers
219 papers, 5.3k citations indexed

About

Manuel Cobo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Manuel Cobo has authored 219 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 154 papers in Pulmonary and Respiratory Medicine, 153 papers in Oncology and 37 papers in Cancer Research. Recurrent topics in Manuel Cobo's work include Lung Cancer Treatments and Mutations (140 papers), Lung Cancer Research Studies (72 papers) and Cancer Immunotherapy and Biomarkers (68 papers). Manuel Cobo is often cited by papers focused on Lung Cancer Treatments and Mutations (140 papers), Lung Cancer Research Studies (72 papers) and Cancer Immunotherapy and Biomarkers (68 papers). Manuel Cobo collaborates with scholars based in Spain, United States and France. Manuel Cobo's co-authors include Bartomeu Massutí, Tudor–Eliade Ciuleanu, Gyula Ostoros, Tsveta Milenkova, Alan Webster, Dolores Isla, Enriqueta Felip, Ki Hyeong Lee, Byoung Chul Cho and Fabrice Barlési and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Cancer.

In The Last Decade

Manuel Cobo

204 papers receiving 5.2k citations

Hit Papers

CNS Response to Osimertinib Versus Standard Epidermal Gro... 2015 2026 2018 2022 2018 2015 2022 2020 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
    2018 511 citations Byoung Chul Cho, Manuel Cobo et al. Journal of Clinical Oncology profile →
  2. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
    2015 324 citations Jean‐Charles Soria, Enriqueta Felip et al. The Lancet Oncology profile →
  3. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
    2022 296 citations Byoung Chul Cho, Delvys Rodríguez‐Abreu et al. The Lancet Oncology profile →
  4. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
    2020 290 citations Makoto Nishio, Fabrice Barlési et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Manuel Cobo Spain 30 3.6k 3.4k 1.3k 1.1k 565 219 5.3k
Jin‐Ji Yang China 36 3.5k 1.0× 3.9k 1.1× 1.2k 0.9× 1.1k 1.0× 306 0.5× 146 4.9k
Willemijn S.M.E. Theelen Netherlands 16 3.0k 0.8× 3.3k 1.0× 998 0.7× 873 0.8× 385 0.7× 33 4.4k
Simon Ekman Sweden 25 2.2k 0.6× 2.5k 0.7× 1.4k 1.0× 1.0k 0.9× 381 0.7× 116 4.2k
Hiroaki Akamatsu Japan 28 3.5k 1.0× 3.8k 1.1× 1.2k 0.9× 1.1k 1.0× 220 0.4× 144 5.1k
Gene Grant Finley United States 19 3.3k 0.9× 2.2k 0.6× 961 0.7× 466 0.4× 690 1.2× 70 4.4k
Noemı́ Reguart Spain 41 2.9k 0.8× 2.6k 0.8× 2.5k 1.9× 875 0.8× 419 0.7× 175 5.5k
Erminia Massarelli United States 32 3.2k 0.9× 2.1k 0.6× 1.2k 0.9× 648 0.6× 729 1.3× 140 4.6k
Tiziana Usari Italy 17 3.1k 0.8× 3.5k 1.0× 1.2k 0.9× 1.0k 0.9× 235 0.4× 51 4.4k
Venice Archer United Kingdom 9 3.6k 1.0× 3.6k 1.0× 919 0.7× 663 0.6× 276 0.5× 16 4.6k
Martin Sebastian Germany 27 4.1k 1.1× 3.3k 1.0× 1.7k 1.3× 930 0.8× 945 1.7× 117 5.8k

Countries citing papers authored by Manuel Cobo

Since Specialization
Citations

This map shows the geographic impact of Manuel Cobo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Cobo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Cobo more than expected).

Fields of papers citing papers by Manuel Cobo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuel Cobo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Cobo. The network helps show where Manuel Cobo may publish in the future.

Co-authorship network of co-authors of Manuel Cobo

This figure shows the co-authorship network connecting the top 25 collaborators of Manuel Cobo. A scholar is included among the top collaborators of Manuel Cobo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuel Cobo. Manuel Cobo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Solomon, Benjamin, Daniel S.W. Tan, Gilberto de Castro, et al.. (2025). The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials. Cancer Research Communications. 5(4). 632–646. 1 indexed citations
3.
Timilsina, Mohan, María Torrente, Mariano Provencio, et al.. (2025). Large language model vs. traditional machine learning: Evaluating predictive models for early detection of tumor relapse. Expert Systems with Applications. 283. 127641–127641. 1 indexed citations
4.
Reck, Martin, Jyoti D. Patel, Jhanelle E. Gray, et al.. (2025). First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study. Journal of Thoracic Oncology. 21(3). 103509–103509.
5.
Zhao, Jun, Amanda Tufman, Lecia V. Sequist, et al.. (2025). OA08.03 COMPEL: Osimertinib + Platinum-Based Chemotherapy in Patients With EGFRm Advanced NSCLC and Progression on 1L Osimertinib. Journal of Thoracic Oncology. 20(10). S27–S27.
6.
7.
Provencio, Mariano, Haroon Hasan, Begoña Campos, et al.. (2024). Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer. Clinical & Translational Oncology. 26(6). 1384–1394. 3 indexed citations
8.
Reck, Martin, Tudor–Eliade Ciuleanu, Michael Schenker, et al.. (2024). Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.. Journal of Clinical Oncology. 42(16_suppl). 8560–8560. 6 indexed citations
9.
Oliver, Javier, Manuel Cobo, José Carlos Benítez, et al.. (2023). Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade. Cancers. 15(13). 3357–3357. 3 indexed citations
10.
Isla, Dolores, J. Casal, Manuel Cobo, et al.. (2023). PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Journal of Clinical Medicine. 12(15). 5063–5063. 6 indexed citations
11.
12.
Yang, James Chih‐Hsin, Paul Mitchell, Thomas John, et al.. (2023). 1325P Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations. Annals of Oncology. 34. S765–S765. 7 indexed citations
13.
Cho, Byoung Chul, Delvys Rodríguez‐Abreu, Maen Hussein, et al.. (2022). Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. The Lancet Oncology. 23(6). 781–792. 296 indexed citations breakdown →
14.
Majem, Margarita, Manuel Cobo, Dolores Isla, et al.. (2021). PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis. Journal of Clinical Medicine. 10(7). 1365–1365. 15 indexed citations
15.
Dómine, Manuel, Teresa Morán, Dolores Isla, et al.. (2020). SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). Clinical & Translational Oncology. 22(2). 245–255. 40 indexed citations
16.
Nishio, Makoto, Fabrice Barlési, Howard West, et al.. (2020). Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.. Journal of Thoracic Oncology. 7 indexed citations
17.
18.
19.
Glisson, Bonnie S., Andrzej Każarnowicz, Kristiaan Nackaerts, et al.. (2013). A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 2 STUDY OF GANITUMAB OR RILOTUMUMAB WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (SCLC). Journal of Thoracic Oncology. 8. 4 indexed citations
20.
Cobo, Manuel, et al.. (2008). Quimioterapia basada en el perfil genético en carcinoma broncogénico en estadio IV.. 20(4). 191–194.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jin‐Ji Yang Breakdown of academic impact, for papers by Willemijn S.M.E. Theelen Breakdown of academic impact, for papers by Simon Ekman Breakdown of academic impact, for papers by Hiroaki Akamatsu Breakdown of academic impact, for papers by Gene Grant Finley Breakdown of academic impact, for papers by Noemı́ Reguart Breakdown of academic impact, for papers by Erminia Massarelli Breakdown of academic impact, for papers by Tiziana Usari Breakdown of academic impact, for papers by Venice Archer Breakdown of academic impact, for papers by Martin Sebastian
Rankless by CCL
2026